Recognizing the potential to help more people who have obesity, Novo Nordisk designed new studies testing semaglutide for weight loss, which led to the creation and approval of Wegovy
The proportion of users with an obesity diagnosis increased from 5% to 10% from 2019 to 2022, and the proportion of users without either a diabetes or obesity diagnosis increased from 9% to 11% over the same period
Many patients can transition from semaglutide to tirzepatide under medical supervision
Scott Malkinsons diagnosis, often called juvenile diabetes, is a heavily genetic condition affecting the pancreas ability to create its own insulin from a young age and can affect a child despite their otherwise healthy diet/exercise, while type 2 diabetes, also known as adult diabetes, can be caused by both genetic and lifestyle factors, such as eating a cereal bomb while taking a shit to make room for more cereal bomb
Meal Plans included so you know what to eat